Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of international phase 3 clinical trials which suggest that Vorasidenib could offer a new treatment option for low-grade glioma; and whether they intend to make it available to brain tumour patients.

If the manufacturer applies for a marketing authorisation in the United Kingdom, the Medicines and Healthcare products Regulatory Agency will consider clinical trial evidence in making a licensing decision. Subject to licensing, the National Institute for Health and Care Excellence will consider the clinical trial evidence, when making decisions on whether vorasidenib should be recommended for routine National Health Service funding.